Centre, not states, to control drug production, moots revised draft bill
The Centre wants the country’s apex drug regulatory body to control the manufacture of drugs or cosmetics instead of the state drug regulators, as is the practice currently. Proposing that the Central Drugs Standard Control Organisation (CDSCO) be empowered to do so, the Centre has sent the revised draft of the New Drugs, Medical Devices and Cosmetics Bill, 2023, for inter-ministerial consultations.
However, the sale of drugs, cosmetics and medical devices will continue to be regulated by the respective state governments, according to the revised draft of the bill, which seeks to replace the existing Drugs and Cosmetics Act of 1940.
Furthermore, PTI reported that the provision of taking permission to operate an e-pharmacy has been removed and replaced with the following words in the draft bill: “…central government may regulate, restrict or prohibit the sale, stocking, exhibiting or offer for sale or distribution of any drug by online mode by notification.”
From states to Centre
The draft New Drugs, Medical Devices and Cosmetics Bill was placed in the public domain in July last year, seeking feedback from stakeholders. The Union health ministry and the CDSCO received several comments from the stakeholders on the draft bill, which was revised accordingly by the ministry and sent for inter-ministerial consultations.
During the ongoing consultations, government think-tank NITI Aayog endorsed the newly-introduced provision of giving the powers to the CDSCO to issue manufacturing licences for drugs and cosmetics instead of the state regulators, saying it will ensure uniform and effective implementation of the law and it implies a huge change towards resting all manufacturing duties with a central licensing authority.
Also read: Gambia cough syrup deaths expose dirty underbelly of Indian pharma
Section 22(c) of the draft bill says: “Manufacture for sale or distribution, any drug or cosmetic, except under and in accordance with a licence issued by the central licensing authority in such form and manner as may be prescribed….”
Currently, all manufacturing activities relating to drugs and cosmetics are regulated by the respective state governments through their drug control organisations. Once the proposed bill is passed by Parliament, all the powers of the state governments relating to the regulation of drugs and cosmetics manufacture will go to the Centre through the CDSCO, an official source explained.
CDSCO must be strengthened
At present, almost every district in the country has state drug control offices to administer provisions relating to the manufacture and sale of drugs and cosmetics. For effective implementation of the newly-introduced provision and regulation of drugs and cosmetics manufacture by the CDSCO, it must be strengthened accordingly in terms of infrastructure and manpower, the source said.
Besides, regulations for the conduct of clinical trials for new drugs and medical devices have been brought under the draft bill.
Currently, the conduct of clinical trials for new drugs and medical devices and the provisions for compensation for injury or death on account of participation in clinical trials, medical management of the trial participants, regulation of the ethics committee, etc., are governed by the New Drugs and Clinical Trials Rules, 2019. Also, medical devices are treated as drugs and there is no separate definition for those.
Also read: Cough syrup deaths in Uzbekistan: 3 employees of Noida firm arrested
Sowa-rigpa, homeopathy to be added
The draft bill also has a separate chapter on AYUSH drugs, which proposes to regulate sowa-rigpa and homeopathy for the first time. The existing act regulates only ayurveda, unani, and siddha drugs and cosmetics.
The draft bill has introduced various definitions or provisions, such as bioequivalence study, bioavailability study, clinical trial, clinical investigation, controlling authority, manufacturer, medical device, new drugs, over-the-counter (OTC) drugs, adulterated cosmetics, etc., for more clarity and smooth functioning and implementation, an official said.
The penalties for offences related to the import of drugs and cosmetics have been enhanced appropriately in the draft bill, another official said.
Regulation of clinical trials
The proposed bill provides for the regulation of clinical trials of new drugs, investigational new drugs, the ethics committee, etc.
“However, in the interest of public health or extreme urgency of drugs, the central government is empowered to make provisions for the central licensing authority to waive the requirement of conducting clinical trial for manufacture or import of new drugs or investigational new drugs in the country,” the draft bill reads.
“Where any participant is injured on account of his participation in the clinical investigation, the person, sponsor, clinical research organisation, any other organisation or investigator permitted under sub-section (1) of section 116 shall provide medical management to that participant,” it states.
Also read: Indian cough syrups smuggled to Bangladesh for tipplers: BSF report
In the existing rules, there is no provision to impose penalties, such as imprisonment, on the erring firms or people for a failure to provide compensation to the participants in the clinical trials for both drugs and medical devices.
(With agency inputs)
